Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Assessment of the Safety and Efficacy of the Minnow Medical GRST™ Peripheral Catheter System

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is ≥18 of age.~2. Patient is Rutherford category 2-4.~3. De novo single lesion with a diameter stenosis (%DS) of ≥50%~4. Target lesion is a de novo occlusion that can be successfully pre-dilated resulting in a lesion of \<99%.~5. Target lesion stenosis has a length of ≤100 mm based on visual assessment.~6. Target vessel reference diameter is ≥3.0 mm and ≤7.0 mm based on visual assessment.~7. Angiographic evidence of distal runoff defined as minimum one patent tibial artery with a straight flow to the foot.~8. Patient is willing and able to provide written informed consent prior to any study specific procedure.~9. Patient is willing and able to comply with specified follow-up evaluations at the specified times.~Exclusion Criteria:~1. Prior PTA in the intended target lesion including 10 mm proximal or distal from the intended treatment area.~2. Evidence of thrombus in the target vessel.~3. Prior ipsilateral or contralateral lower limb arterial bypass.~4. Treatment of ipsilateral lesions during the index procedure or planned treatment after the index procedure.~5. Target lesion is severely calcified.~6. Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Heparin, contrast agents (that cannot be adequately pre-medicated).~7. Any planned surgery within 30 days of the study procedure.~8. Renal failure (serum creatinine \> 2.0 mg/dL).~9. Female with childbearing potential without a negative pregnancy test.~10. Patient has had an organ transplant.~11. Patient is currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the endpoints of this study.~12. In the investigator's opinion, the patient has a severe co-morbid condition(s) that could limit the ability to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): GRST Peripheral Catheter System

Based on this trial design, predict the completion outcome and termination type (if applicable).